Emerging Company Profile
A2: targeting lost genetic material to distinguish tumors from normal cells
A2 will use its $71.5M series B to advance up to three clinical solid tumor programs
A2 uses its dual engineered T cell platform to kill tumor cells while protecting healthy cells by targeting the loss of genetic material.
Oct 9, 2020 | 10:14 PM GMT